PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27178121-11	2016	Dual inhibition of Ras signaling via Ral and Raf, using a combination of small-molecule inhibitor RBC8 and sorafenib, reduced the proliferation of HCC cells in culture and completely inhibited their growth as xenograft tumors in nude mice.	Sorafenib	107-116	zinc fingers and homeoboxes 2	Mus musculus	45-48	
29196297-5	2018	The cytotoxicity of sorafenib and aspirin was blocked by inhibition of the AMPK or ERK pathways through shRNA or via pharmacologic inhibitors of RAF (LY3009120), MEK (trametinib), or AMPK (compound C).	Sorafenib	20-29	zinc fingers and homeoboxes 2	Mus musculus	145-148	
29196297-7	2018	In vivo treatment of human xenografts in NSG mice with sorafenib and aspirin significantly reduced tumor volume compared with each single-agent treatment.Conclusions: Combination sorafenib and aspirin exerts cytotoxicity against RAS/RAF-mutant cells by simultaneously affecting two independent pathways and represents a promising novel strategy for the treatment of RAS-mutant cancers.	Sorafenib	55-64	zinc fingers and homeoboxes 2	Mus musculus	233-236	
29196297-7	2018	In vivo treatment of human xenografts in NSG mice with sorafenib and aspirin significantly reduced tumor volume compared with each single-agent treatment.Conclusions: Combination sorafenib and aspirin exerts cytotoxicity against RAS/RAF-mutant cells by simultaneously affecting two independent pathways and represents a promising novel strategy for the treatment of RAS-mutant cancers.	Sorafenib	179-188	zinc fingers and homeoboxes 2	Mus musculus	233-236	
29463989-3	2018	However, incomplete inhibition of RAF activity by sorafenib may also induce paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in malignant cells.	Sorafenib	50-59	zinc fingers and homeoboxes 2	Mus musculus	34-37	
22753710-9	2012	Sorafenib and PI-103 as single agents differentially inhibited or activated key enzymes (MEK, ERK, AKT, mTOR, and S6K) in PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.	Sorafenib	0-9	zinc fingers and homeoboxes 2	Mus musculus	144-147	
22753710-13	2012	CONCLUSION: The combination of PI-103 and sorafenib has the advantage over mono-drug therapy on inhibition of HCC cell proliferation and tumorigenesis by inhibiting both PI3K/AKT/mTOR and RAS/RAF/MAPK signaling pathways.	Sorafenib	42-51	zinc fingers and homeoboxes 2	Mus musculus	192-195	
20201822-5	2010	Recently, we have reported that the multi-kinase and potent Raf inhibitor sorafenib reversed memory impairment and reduced the expression of APP, Cox-2, and iNOS in the brain of the transgenic mouse model of AD, APPswe.	Sorafenib	74-83	zinc fingers and homeoboxes 2	Mus musculus	60-63	
15171791-13	2004	In contrast, the Raf inhibitor BAY 43-9006 did not influence adenoma formation in vivo.	Sorafenib	31-42	zinc fingers and homeoboxes 2	Mus musculus	17-20	
22941213-3	2013	We demonstrate that the growth of the NIH 3T3/Mdr cell line was affected in a dose-dependent manner more significantly by the pan-Raf inhibitor sorafenib than by the selective mutant B-Raf inhibitor PLX4720.	Sorafenib	144-153	zinc fingers and homeoboxes 2	Mus musculus	130-133	
22960170-7	2012	Sorafenib, whose targets include not only PDGFRA but also the Src downstream target Raf, was effective at inhibiting mouse and human tumor cell growth and halted progression of mouse aRMS tumors in vivo.	Sorafenib	0-9	zinc fingers and homeoboxes 2	Mus musculus	84-87	
21593445-13	2011	Sorafenib, a therapeutic agent targeting Raf kinases, decreases CXCL8 expression in melanoma cells through reexpression of TTP.	Sorafenib	0-9	zinc fingers and homeoboxes 2	Mus musculus	41-44